Alphagan P

Base Information

• Chemical Name: Alphagan P
• CAS No.: 70359-46-5
• Molecular Formula: C11H10BrN5^.C4H6O6
• Molecular Weight: 442.22
• Hs Code.: 29332900
• European Community (EC) Number: 629-848-5
• DSSTox Substance ID: DTXSID20426066
• Wikidata: Q27122452
• NCI Thesaurus Code: C47419
• RXCUI: 39171
• Mol file: 70359-46-5.mol

Synonyms:5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate;5-bromo-6-(imidazolidinylideneamino)quinoxaline;5-bromo-6-(imidazolin-2-ylamino)quinoxaline;AGN 190342;AGN-190342;AGN190342;Alphagan;Alphagan P;brimonidine;brimonidine Purite;brimonidine tartrate;brimonidine tartrate (1:1);brimonidine tartrate (1:1), (S-(R*,R*))-isomer;brimonidine tartrate, (R-(R*,R*))-isomer;bromoxidine;mirvaso;Ratio Brimonidine;ratio-Brimonidine;Sanrosa;UK 14,304;UK 14,304 18;UK 14,304-18;UK 14,30418;UK 14,308;UK 14304;UK 14308;UK-14,304-18;UK-14,308;UK-14304;UK14,30418;UK14,308;UK14304

Chemical Property of Alphagan P

Chemical Property:

• Appearance/Colour: Off-white crystalline solid
• Vapor Pressure: 1.1E-07mmHg at 25°C
• Melting Point: 207-208 °C (dec.)
• Boiling Point: 432.6 °C at 760 mmHg
• Flash Point: 215.4 °C
• PSA: 177.26000
• LogP: -0.52180
• Storage Temp.: -20°C Freezer
• Hydrogen Bond Donor Count: 6
• Hydrogen Bond Acceptor Count: 9
• Rotatable Bond Count: 5
• Exact Mass: 441.02840
• Heavy Atom Count: 27
• Complexity: 442

Purity/Quality:

98%min ^*data from raw suppliers

UK 14,304 tartrate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Canonical SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O
• Isomeric SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O
• Recent ClinicalTrials: Safety and Efficacy Study BRIMOCHOL? PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
• Recent EU Clinical Trials: A Multi-Center, Investigator-Masked, Randomized, Crossover, Equivalence Study of the Safety and Efficacy of Once Daily Brimonidine Tartrate 0.35% Ophthalmic
• Recent NIPH Clinical Trials: A phase I clinical pharmacology study of SJP-0125
• Description: Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells). It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution. It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day. Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
• Uses: It is an a 2 receptor agonist. It is a drug used to treat glaucoma. It acts via decreasing aqueous humor synthesis It is an α2 receptor agonist. It is a drug used to treat glaucoma. Used to treat open-angle glaucoma or ocular hypertension